120 related articles for article (PubMed ID: 21708827)
1. Kupffer cell activation and portal hypertension.
Steib CJ
Gut; 2011 Oct; 60(10):1307-8. PubMed ID: 21708827
[No Abstract] [Full Text] [Related]
2. Kupffer cells are activated in cirrhotic portal hypertension and not normalised by TIPS.
Holland-Fischer P; Grønbæk H; Sandahl TD; Moestrup SK; Riggio O; Ridola L; Aagaard NK; Møller HJ; Vilstrup H
Gut; 2011 Oct; 60(10):1389-93. PubMed ID: 21572121
[TBL] [Abstract][Full Text] [Related]
3. Soluble CD163, a marker of Kupffer cell activation, is related to portal hypertension in patients with liver cirrhosis.
Grønbaek H; Sandahl TD; Mortensen C; Vilstrup H; Møller HJ; Møller S
Aliment Pharmacol Ther; 2012 Jul; 36(2):173-80. PubMed ID: 22591184
[TBL] [Abstract][Full Text] [Related]
4. The soluble mannose receptor is released from the liver in cirrhotic patients, but is not associated with bacterial translocation.
Laursen TL; Rødgaard-Hansen S; Møller HJ; Mortensen C; Karlsen S; Nielsen DT; Frevert S; Clemmesen JO; Møller S; Jensen JS; Bendtsen F; Grønbaek H
Liver Int; 2017 Apr; 37(4):569-575. PubMed ID: 27706896
[TBL] [Abstract][Full Text] [Related]
5. Effects of splenic artery occlusion on portal pressure in patients with cirrhosis and portal hypertension.
Luca A; Miraglia R; Caruso S; Milazzo M; Gidelli B; Bosch J
Liver Transpl; 2006 Aug; 12(8):1237-43. PubMed ID: 16741929
[TBL] [Abstract][Full Text] [Related]
6. Portal blood flow, effective hepatic blood flow, and outcome after partial portal decompression.
Rosemurgy AS; Thometz DP; Zervos EE
J Surg Res; 2004 Mar; 117(1):64-70. PubMed ID: 15013716
[TBL] [Abstract][Full Text] [Related]
7. Modification of splenic stiffness on acoustic radiation force impulse parallels the variation of portal pressure induced by transjugular intrahepatic portosystemic shunt.
De Santis A; Nardelli S; Bassanelli C; Lupo M; Iegri C; Di Ciesco CA; Forlino M; Farcomeni A; Riggio O
J Gastroenterol Hepatol; 2018 Mar; 33(3):704-709. PubMed ID: 28753738
[TBL] [Abstract][Full Text] [Related]
8. Favorable clinical outcome using a covered stent following transjugular intrahepatic portosystemic shunt in patients with portal hypertension.
Wu X; Ding W; Cao J; Han J; Huang Q; Li N; Li J
J Hepatobiliary Pancreat Sci; 2010 Sep; 17(5):701-8. PubMed ID: 20703849
[TBL] [Abstract][Full Text] [Related]
9. Covered transjugular intrahepatic portosystemic stents maintain lower portal pressure and require fewer reinterventions than uncovered stents.
Ockenga J; Kroencke TJ; Schuetz T; Plauth M; Kasim E; Petersein J; Schmidt HH; Lochs H
Scand J Gastroenterol; 2004 Oct; 39(10):994-9. PubMed ID: 15513340
[TBL] [Abstract][Full Text] [Related]
10. No difference in portal and hepatic venous bacterial DNA in patients with cirrhosis undergoing transjugular intrahepatic portosystemic shunt insertion.
Mortensen C; Karlsen S; Grønbæk H; Nielsen DT; Frevert S; Clemmesen JO; Møller S; Jensen JS; Bendtsen F
Liver Int; 2013 Oct; 33(9):1309-15. PubMed ID: 23763259
[TBL] [Abstract][Full Text] [Related]
11. [Transjugular intrahepatic portosystemic shunt in treatment of portal hypertension].
Tarazov PG
Khirurgiia (Mosk); 1999; (7):64-9. PubMed ID: 10459195
[No Abstract] [Full Text] [Related]
12. Urinary aquaporin-2 excretion before and after transjugular intrahepatic portosystemic shunt insertion for refractory ascites.
Geilswijk M; Thomsen KL; Pedersen EB; Vilstrup H; Grønbæk H
Scand J Gastroenterol; 2015 Apr; 50(4):454-61. PubMed ID: 25637473
[TBL] [Abstract][Full Text] [Related]
13. Transjugular intrahepatic porto-systemic shunt to relieve refractory ascites in a patient with cirrhosis and portal hypertension.
Joseph G; George OK; Jayanthi V
Indian Heart J; 2002; 54(6):731-2. PubMed ID: 12674194
[No Abstract] [Full Text] [Related]
14. Combined transjugular intrahepatic portosystemic shunt and other interventions for hepatocellular carcinoma with portal hypertension.
Qiu B; Zhao MF; Yue ZD; Zhao HW; Wang L; Fan ZH; He FL; Dai S; Yao JN; Liu FQ
World J Gastroenterol; 2015 Nov; 21(43):12439-47. PubMed ID: 26604651
[TBL] [Abstract][Full Text] [Related]
15. CXCL9 is a prognostic marker in patients with liver cirrhosis receiving transjugular intrahepatic portosystemic shunt.
Berres ML; Asmacher S; Lehmann J; Jansen C; Görtzen J; Klein S; Meyer C; Strunk HM; Fimmers R; Tacke F; Strassburg CP; Trautwein C; Sauerbruch T; Wasmuth HE; Trebicka J
J Hepatol; 2015 Feb; 62(2):332-9. PubMed ID: 25457205
[TBL] [Abstract][Full Text] [Related]
16. [Role of transjugular intrahepatic portosystemic shunt (TIPS) in the treatment of portal hypertension complications].
Xu K; Han GH
Zhonghua Gan Zang Bing Za Zhi; 2011 Jul; 19(7):481-2. PubMed ID: 22152232
[No Abstract] [Full Text] [Related]
17. Invasive and non-invasive assessment of portal hypertension.
Leung JC; Loong TC; Pang J; Wei JL; Wong VW
Hepatol Int; 2018 Feb; 12(Suppl 1):44-55. PubMed ID: 28361299
[TBL] [Abstract][Full Text] [Related]
18. Unsuccessful transjugular intrahepatic portosystemic shunt for a patient with right heart failure and portal hypertension.
Graus L; Verresen L; De Vusser P; Verbrugge FH; Caenepeel P
Acta Gastroenterol Belg; 2017; 80(1):63-66. PubMed ID: 29364100
[TBL] [Abstract][Full Text] [Related]
19. Role of transjugular intrahepatic portosystemic shunt in the management of portal hypertension.
Parker R
Clin Liver Dis; 2014 May; 18(2):319-34. PubMed ID: 24679497
[TBL] [Abstract][Full Text] [Related]
20. [Hemolytic anemia secondary to the placement of a portosystemic stented shunt].
Carrillo-Esper R; Carrillo-Cortes U; Carrillo-Córdova JR; Carrillo-Córdova LD; Carrillo-Córdova CA; Carrillo-Córdova DM
Cir Cir; 2013; 81(2):143-7. PubMed ID: 23522316
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
